Distant Triggers of IgAN (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #TH-PO0519; Pres time: Oct 22, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "He received adalimumab from 2021-2023 and then transitioned to secukinumab given concerns for worsening fatigue due to adalimumab...The patient continues to remain on secukinumab with avoidance of TNF-alpha inhibitors; and was started on sparsentan to aid in reduction of glomerular pressure...-Consider secondary causes of IgAN in patients with inflammatory/autoimmune conditions and extensive drug exposures. -Treatment of secondary IgAN involves addressing underlying triggers in addition to standard treatments targeting IgAN pathogenesis."
Fibrosis • Glomerulonephritis • IgA Nephropathy • Immunology • Infectious Disease • Inflammatory Arthritis • Plaque Psoriasis • Psoriasis • Psoriatic Arthritis • Renal Disease • Seronegative Spondyloarthropathies
|
|
Neha Vijay Vaidya; Piera A. Sosa; Zoltan G. Laszik; Christopher R. Showers
|